ANSWERS (VERIFIED ANSWERS) PLUS RATIONALES
Q&A 2026 |INSTANT DOWNLOAD
1. Which of the following best describes the primary goal of
Continuous Glucose Monitoring (CGM)?
A. To measure blood pressure trends
B. To continuously track glucose levels in real-time
C. To replace insulin therapy
D. To diagnose type 2 diabetes only
Rationale:
• A – Incorrect. CGM monitors glucose, not blood pressure.
• B – Correct. CGM devices provide real-time glucose
readings to improve glycemic control.
• C – Incorrect. CGM assists therapy but does not replace
insulin.
• D – Incorrect. CGM is used for both type 1 and type 2
diabetes management.
Answer: B
2. Which factor most influences HbA1c levels?
,A. Fasting glucose only
B. Average glucose over the past 2–3 months
C. Daily exercise intensity
D. Blood pressure
Rationale:
• A – Incorrect. HbA1c reflects long-term glucose, not a
single fasting reading.
• B – Correct. HbA1c indicates average glucose over 8–12
weeks.
• C – Incorrect. Exercise affects glucose acutely but not
directly HbA1c.
• D – Incorrect. Blood pressure does not determine HbA1c.
Answer: B
3. What is the primary mechanism of action of rapid-acting
insulin?
A. Slow glucose absorption
B. Rapid reduction of postprandial glucose
C. Long-term basal glucose control
D. Stimulates pancreatic beta-cell growth
Rationale:
• A – Incorrect. Insulin facilitates glucose uptake; it doesn’t
slow absorption.
, • B – Correct. Rapid-acting insulin reduces post-meal glucose
spikes.
• C – Incorrect. Basal insulin controls fasting glucose.
• D – Incorrect. Exogenous insulin does not stimulate beta-
cell proliferation.
Answer: B
4. Which of the following are complications associated with
poorly controlled diabetes?
A. Retinopathy
B. Nephropathy
C. Neuropathy
D. All of the above
Rationale:
• A – True. Chronic hyperglycemia damages retinal blood
vessels.
• B – True. Diabetic nephropathy affects kidneys.
• C – True. Neuropathy results from prolonged high glucose.
• D – Correct. All options are common microvascular
complications.
Answer: D
, 5. Continuous Subcutaneous Insulin Infusion (CSII) therapy is
indicated for:
A. Only type 2 diabetes patients
B. Type 1 diabetes patients requiring tight glucose control
C. Patients who avoid carbohydrate counting
D. Individuals without diabetes
Rationale:
• A – Incorrect. CSII is mainly used in type 1 diabetes.
• B – Correct. CSII (insulin pump) helps maintain stable
glucose in type 1 patients.
• C – Incorrect. Carbohydrate counting is essential for
dosing.
• D – Incorrect. Non-diabetic patients don’t need CSII.
Answer: B
6. The recommended premeal glucose target according to
AACE guidelines is:
A. 50–70 mg/dL
B. 80–130 mg/dL
C. 140–180 mg/dL
D. 200–250 mg/dL
Rationale:
• A – Too low, risk of hypoglycemia.